Surface Derivatization of Zirconium Phosphate Nanoplatelets: Potential Nanocarrier of Doxorubicin Anticancer Drug

4^th European Chemistry Congress

May 11-13, 2017 Barcelona, Spain

Julissa Gonzalez Villegas

University of Puerto, United States

Posters & Accepted Abstracts: Chem Sci J

Abstract :

Surface modification of doxorubicin anticancer drug (DOX) intercalated zirconium phosphate (ZrP) nanoparticles (DOX@ZrP) is proposed to improve the potential of this drug delivery system for cancer therapy. The surface of DOX@ZrP nanoparticles was modified with an amorphous layer of Zr(IV) followed by modification with monomethyl-polyethylene glycol-monophosphate (m-PEG-PO3) to increase the DOX@ZrP biocompatibility. 31P{1H}MAS NMR data shows a new peak at -26 ppm corresponding to the PO43- groups coordinated with Zr(IV) on the surface. m-PEG-PO3/Zr(IV)/DOX@ZrP spectra shows no additional resonance centered at �´ of -22.6 ppm generated by proton-phosphorous cross polarization indicating no partial PEG intercalation in the interlaminar space. Simulated body fluid (SBF) was used to determine the in vitro release of DOX from DOX@ZrP, Zr(IV)/DOX@ ZrP, and m-PEG-PO3/ Zr(IV)/DOX@ZrP. MTS cell viability assay reveal that m-PEG-PO3/ Zr(IV)/DOX@ZrP exhibited a 20% increase in the toxicity comparing with free DOX when PC3 cells are exposed for 48 h. m-PEG-PO3 polymer coating of DOX@ZrP nanoparticles promise to have a strong impact on the targeting, distribution and degradation of the nanoparticles under physiological environment that should result in a more efficient chemotherapy agent than free doxorubicin. jgonvi1888@gmail.com